Adesis Announces Linda Choi MacDonald as New Chief Operating Officer
August 30 2021 - 4:15PM
Business Wire
Adesis, Inc., a leading contract research organization and a
wholly-owned subsidiary of Universal Display Corporation
(Nasdaq:OLED), today announced that Linda Choi MacDonald has joined
the company as Chief Operating Officer. MacDonald brings more than
25 years of experience in the biopharmaceutical industry, including
leading organizations in the Americas, Europe and Asia-Pacific
regions. As COO, MacDonald is responsible for overseeing Adesis’
P&L, operations and strategy.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210830005106/en/
Linda Choi MacDonald, COO of Adesis, Inc.
(Photo: Business Wire)
“I am delighted to welcome Linda to Adesis,” said Andrew
Cottone, Ph.D., President of Adesis, Inc. “Adding Linda’s breadth
of commercial, R&D and G&A experience and her international
background in the biopharmaceutical industry to our extraordinary
chemistry and leadership teams is expected to expand our expertise
as a world-class CRO.”
“Vitalizing people and achieving pioneering results are
principles I share with Adesis,” said Linda Choi MacDonald. “I am
excited to work with the Adesis team on the innovative strategies
and disciplined execution that advance our customers’ ideas to
market faster.”
Prior to joining Adesis, MacDonald served as Chief Operations
Officer at Avanir Pharmaceuticals, a subsidiary of Otsuka
Pharmaceutical. Previously, she was Vice President of Global
Marketing & Patient Access Operations, Vice President of Talent
Services Asia Pacific, and Head of Global Customer-Facing
Excellence Strategy & Operations at UCB Biopharma, and held
various positions of increasing responsibility at Eli Lilly and
Company across its commercial organizations. Her track record of
success led her to be recognized as a 2020 HBA (Healthcare
Businesswomen's Association) Luminary Award recipient for being a
“shining example of transformational leadership.”
About Adesis, Inc.
As a wholly-owned subsidiary of Universal Display Corporation,
Adesis is a contract research organization (CRO) supporting the
pharma, biotech, catalysis and a number of other industries. The
CRO specializes in organic and organometallic synthesis, in
milligrams to multi-kilogram quantities. Adesis has a business
model of providing clients with organic chemistry services in three
areas: early stage research, scale up and development, and
specialty manufacturing. With over 20 years of success and
approximately 100 chemists with extensive industry and professional
experience, Adesis supports companies in various industries with
small molecule organic chemistry expertise. Adesis provides a range
of services that can supplement research and development efforts.
It can also act as a specialty manufacturer to reinforce supply
chains and protect sensitive intellectual property. To learn more
about Adesis, please visit http://adesisinc.com/.
About Universal Display Corporation
Universal Display Corporation (Nasdaq: OLED) is a leader in the
research, development and commercialization of organic light
emitting diode (OLED) technologies and materials for use in display
and solid-state lighting applications. To learn more about
Universal Display Corporation, please visit https://oled.com.
Universal Display Corporation and the Universal Display
Corporation logo are trademarks or registered trademarks of
Universal Display Corporation. All other company, brand or product
names may be trademarks or registered trademarks.
All statements in this document that are not historical, such as
those relating to the Company’s technologies and potential
applications of those technologies, the Company’s expected results
and future declaration of dividends, as well as the growth of the
OLED and CRO market and the Company’s opportunities in that market,
are forward-looking financial statements within the meaning of the
Private Securities Litigation Reform Act of 1995. You are cautioned
not to place undue reliance on any forward-looking statements in
this document, as they reflect Universal Display Corporation’s
current views with respect to future events and are subject to
risks and uncertainties that could cause actual results to differ
materially from those contemplated. These risks and uncertainties
are discussed in greater detail in Universal Display Corporation’s
periodic reports on Form 10-K and Form 10-Q filed with the
Securities and Exchange Commission, including, in particular, the
section entitled “Risk Factors” in Universal Display Corporation’s
Annual Report on Form 10-K for the year ended December 31, 2020.
Universal Display Corporation disclaims any obligation to update
any forward-looking statement contained in this document.
(OLED-C)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210830005106/en/
Adesis, Inc./ Universal Display Corporation Contact: Darice Liu
investor@oled.com media@oled.com +1 609-964-5123
Universal Display (NASDAQ:OLED)
Historical Stock Chart
From Apr 2024 to May 2024
Universal Display (NASDAQ:OLED)
Historical Stock Chart
From May 2023 to May 2024